All In Biotech

Drug Trial Radar · NCT06122610

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Dosimetry-Guided 177Lu-DOTATATE Treatment Planning Using 64Cu-DOTATATE as a Surrogate

Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

4

Actual

Start

Mar 7, 2025

Primary completion

May 31, 2026

Study completion May 31, 2026

Sponsor

Lead sponsor
University of Wisconsin, MadisonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans

Conditions

  • Neuroendocrine Tumors
  • Somatostatin Receptor-positive Neuroendocrine Tumor

Interventions

  • Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)Device

    SPECT/CT will be performed after first cycle of Lutathera® treatment

  • Photon Emission Tomography / CT (PET/CT)Device

    PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment

  • 64Cu-DotatateDrug

    Standard of care administration of radioactive drug for PET/CT

  • 177Lu-DotatateDrug

    Standard of care administration of radioactive drug for PET/CT and SPECT/CT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare pre-therapy and post-therapy voxel-based dosimetry estimatesTime frame: Baseline and 120 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Wisconsin - Madison

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.